ROIVHealthcare · BiotechnologyThe 13 Wall Street analysts covering Roivant Sciences Ltd. hold a median 12-month price target of $47 — +25.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Roivant Sciences Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (93): The shares have been drifting up relative to others.
Accruals (16): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (8): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ROIV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +25.3% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | Citigroup | Maintains | Buy | $46 → $56 |
| 12 Oct 2026 | Wolfe Research | Downgrade | Peer Perform | — |
| 17 Sept 2026 | Stifel | Initiates | Buy | $51 |
| 17 Sept 2026 | Stifel | Initiates | Buy | — |
| 9 Sept 2026 | Guggenheim | Maintains | Buy | $42 → $46 |
| 9 Sept 2026 | Guggenheim | Maintains | Buy | — |
| 9 Sept 2026 | TD Cowen | Maintains | Buy | $50 → $55 |
| 9 Sept 2026 | TD Cowen | Maintains | Buy | — |
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $41 → $47 |
| 8 Sept 2026 | Jefferies | Maintains | Buy | — |
| 8 Sept 2026 | Jefferies | Maintains | Buy | $42 → $52 |
| 28 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $41 |
| 28 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Aug 2026 | Citigroup | Maintains | Buy | — |
| 10 Aug 2026 | Citigroup | Maintains | Buy | $42 → $46 |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $36 → $42 |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $34 → $41 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ROIV appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Roivant Sciences Ltd. returned +100.0% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 1% of US stocks
Cheaper than 15% of US stocks
Cheaper than 89% of US stocks
Higher than 8% of US stocks
Higher than 15% of US stocks
Higher than 91% of US stocks
Higher than 1% of US stocks
Higher than 98% of US stocks
Higher than 37% of US stocks
Higher than 22% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Roivant Sciences Ltd. has a market value of $26.8B and an enterprise value of $23.8B.
Revenue in the twelve months to 30 June 2026: $7.5M. The latest quarter shrank 33.5% year on year.
Net income over the same four quarters: −$414.6M, a −5504.5% net margin.
Diluted earnings per share, trailing twelve months: $−0.53.
Free cash flow in the twelve months to 30 June 2026: −$821.1M.
Roivant Sciences Ltd. spent $317.9M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 1.9×; forward P/E: −21.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Roivant Sciences Ltd. employs 721 people — $10K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Roivant Sciences Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Roivant Sciences discussed Phase 3 results for brepocitinib in non-infectious uveitis, according to a Seeking Alpha transcript.
Why it matters — The discussion concerns clinical results for a Roivant medicine being studied in non-infectious uveitis.
Roivant Sciences reported positive Phase III results from its CLARITY-1 and CLARITY-2 studies evaluating brepocitinib (Brepo) in noninfectious uveitis, an inflammatory eye disease that can result in vision loss.
Why it matters — The results provide a clinical update on Roivant’s evaluation of brepocitinib for noninfectious uveitis.
Roivant and Priovant reported that brepocitinib met the primary endpoint in both Phase 3 CLARITY trials for non-infectious uveitis. The companies also reported statistically significant and clinically meaningful benefits on all key secondary endpoints, including steroid-free quiescence and visual-function measures.
Why it matters — The Phase 3 results provide an update on brepocitinib’s clinical development for non-infectious uveitis, a program relevant to Roivant.
Roivant announced it will host a live conference call and webcast at 8:00 a.m. ET on November 9, 2026, to report financial results for the second quarter ended September 30, 2026, and provide a business update.
Why it matters — ROIV watchers can follow the scheduled call for the company’s quarterly results and business update.
Roivant Sciences CEO Matthew Gline outlined the company's priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant's IMVT-1402, and expansion of its pulmonary hypertension program.
Why it matters — A ROIV watcher would care because the company's stated priorities signal near-term catalysts, including a product launch and key pipeline readouts.
The 13 Wall Street analysts covering Roivant Sciences Ltd. have a median 12-month price target of $47, with estimates ranging from $41 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Roivant Sciences Ltd., 11 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Roivant Sciences Ltd. 36 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Roivant Sciences Ltd. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +25.3% from the last close, and Ticker Nerd's factor model ranks Roivant Sciences Ltd. 36 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Roivant Sciences Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ROIV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $41 to $62 over the next 12 months.
Roivant Sciences Ltd. returned +100.0% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies.
The most recent item we track (Seeking Alpha, 21 Oct 2026): "Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript". Roivant Sciences discussed Phase 3 results for brepocitinib in non-infectious uveitis, according to a Seeking Alpha transcript.
Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies. Roivant Sciences Ltd. operates across immunology, dermatology, and other high-unmet-need therapeutic areas, with current work spanning commercial products and clinical-stage candidates. Its business model emphasizes creating focused operating companies to advance individual drug programs, support partnering activities, and incubate complementary health technology initiatives. The company’s current product and pipeline portfolio includes therapies for autoimmune and inflammatory diseases, as well as treatments being studied in areas such as dermatologic conditions, uveitis, pulmonary hypertension, and rare diseases. Roivant Sciences Ltd. plays a distinctive role in the healthcare market by combining drug development expertise with an asset-centric structure designed to move promising medicines toward commercialization.
CEO Mr. Matthew Gline · 721 employees · United Kingdom · https://roivant.com
